ImmunoRestoration, Inc. is a clinical-stage biopharmaceutical company developing immunotherapeutic cancer vaccine platform for the treatment of multiple types of cancer especially breast cancer.
ImmunoRestoration was founded to lead the development and commercialization of a novel immunotherapeutic cancer vaccine platform based on research and studies done at the University of Pennsylvania; led by Drs. Brian Czerniecki and Gary Koski.
ImmunoRestoration, Inc. is a clinical-stage biopharmaceutical company developing immunotherapeutic cancer vaccine platform for the treatment of multiple types of cancer especially breast cancer.
ImmunoRestoration was founded to lead the development and commercialization of a novel immunotherapeutic cancer vaccine platform based on research and studies done at the University of Pennsylvania; led by Drs. Brian Czerniecki and Gary Koski.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
The companys core technology is a novel, integrated dendritic cell-based immunization system – Immune Conditioning via Activated Innate (autologous) Transfer – ICAIT©, that helps patients battle cancer by rejuvenating their own immune response. It uses dendritic cells (DC) as liaison cells between the T cells and the other cells of the immune system to oversome obstacles facing anti-cancer vaccines.
In Nov 2018, ImmunoRestoration acquired further clinical developmental rights of BB-IND-11043 from Dr. Brian Czerniecki, MD., Ph.D, of the H. Lee Moffitt Cancer Center & Research Institute. The vaccine has been used in more than 100 women with encouraging results, with ImmunoRestoration planning for the upcoming new multi-center, multi-year trials for further platforms development.
Recover your password.
A password will be e-mailed to you.